1. Association of Parkinson’s disease and treatment with aminosalicylates in inflammatory bowel disease: a cross-sectional study in a Spain drug dispensation records
- Author
-
María José Cabello Tapia, Víctor Campos Arillo, Adolfo Mínguez Castellanos, Javier Pinel Ríos, María Rosario Gómez García, Carlos Navarro, María José Piña Vera, María José Pérez Navarro, and Francisco Escamilla Sevilla
- Subjects
Male ,Parkinson's disease ,Cross-sectional study ,alpha-synuclein ,Disease ,Inflammatory bowel disease ,chemistry.chemical_compound ,0302 clinical medicine ,Risk Factors ,Mesalamine ,media_common ,5-ASA ,Aged, 80 and over ,Anti-Inflammatory Agents, Non-Steroidal ,Parkinson Disease ,General Medicine ,Middle Aged ,Neurology ,Medicine ,030211 gastroenterology & hepatology ,Female ,Drug ,medicine.medical_specialty ,media_common.quotation_subject ,prevalence ,03 medical and health sciences ,Age Distribution ,Mesalazine ,inflammatory bowel disease ,Internal medicine ,medicine ,microbiota ,Humans ,Medical prescription ,Sex Distribution ,Aged ,business.industry ,Public health ,Research ,Protective Factors ,medicine.disease ,Inflammatory Bowel Diseases ,Cross-Sectional Studies ,Logistic Models ,chemistry ,Spain ,Parkinson’s disease ,business ,030217 neurology & neurosurgery - Abstract
ObjectivesTo analyse the association between aminosalicylate-treated inflammatory bowel disease (IBD) and Parkinson’s disease (PD) at population level.DesignCross-sectional study.SettingThe study was performed based on electronic drug prescription and dispensation records of the Andalusian Public Health System.ParticipantsAll individuals aged ≥50 years with at least one drug dispensation during December 2014 were identified from the records.Primary and secondary outcome measuresGroups were formed: ‘possible PD’ group, including all who received an anti-Parkinson agent; ‘possible IBD’ group, those treated with mesalazine and/or derivatives (5-aminosalicylic acid (5-ASA)); and ‘possible PD and IBD’, including those receiving both anti-Parkinson agent and 5-ASA. Prevalence of possible PD was determined among those with possible IBD and among those without this condition. The age-adjusted and sex-adjusted OR was calculated.ResultsWe recorded 2 020 868 individuals (68±11 years, 56% female), 19 966 were included in possible PD group (75±9 years, 53% female) and 7485 in possible IBD group (64±10 years, 47% female); only 56 were included in both groups (76±8 years, 32% female). The prevalence of possible PD was 0.7% among those with possible IBD and 1% among those without this condition (adjusted OR=0.94; 95% CI 0.72 to 1.23; p=0.657). OR was 0.28 in individuals aged ≤65 years (95% CI 0.10 to 0.74; p=0.01) and 1.17 in older individuals (95% CI 0.89 to 1.54; p=0.257).ConclusionsWithin the limitations of this study, the results suggest a protective role for IBD and/or 5-ASA against PD development, especially among under 65-year olds. Further studies are warranted to explore this association given its scientific and therapeutic implications.
- Published
- 2019